advanced nanotechnology-based therapies, with a focus on how tumors protect themselves through the tumor microenvironment (TME). Conventional treatments like chemotherapy, radiation, and surgery often struggle because they lack precision, harm healthy cells, and have difficulty reaching advanced tumors. Despite decades of use, these methods have only modestly improved survival rates for late-stage cancers, highlighting the need for better drug delivery strategies.
Tumors are not just made of cancer cells; they exist within a complex environment that actively resists treatment. Dense tissue structures and high internal pressure block drugs from entering, while poor blood supply creates low-oxygen areas that reduce the effectiveness of radiation and chemotherapy. The TME also suppresses the immune system by recruiting cells that help tumors hide from immune attack, making treatment even more challenging.
Nanotherapeutics offer a more targeted and flexible solution. Tiny drug carriers such as liposomes and nanoparticles can accumulate in tumors through leaky blood vessels or be engineered to bind specifically to cancer cells. Some are designed to release drugs only under certain conditions, like acidic tumor environments or external triggers. While these technologies show great promise, challenges remain, including differences between patients’ tumors, manufacturing complexity, and the body’s tendency to clear nanoparticles too quickly. Overall, future cancer therapy is moving toward combining nanotechnology with immune and traditional treatments to weaken the tumor’s protective environment and improve outcomes.